What is the preferred ART regimen for infants under 3 years old?

AIIMS CRE 2025

Child Health Nursing (Pediatrics)

Easy

Appeared in: AIIMS CRE 2025

Explanation

The standard of care for first-line ART in infants under 3 years is a combination of two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and a boosted Protease Inhibitor (PI).
Zidovudine and Lamivudine serve as the recommended NRTI backbone.
Lopinavir is a potent PI that is preferred over Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) for this age group due to its higher efficacy and higher barrier to resistance.
This regimen is effective even if the infant was exposed to NNRTIs for the prevention of mother-to-child transmission (PMTCT).

Option A: This regimen uses Nevirapine, a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). NNRTIs have a lower genetic barrier to resistance and are less preferred than Protease Inhibitors (PIs) as a first-line option for infants, especially if there was prior NNRTI exposure for PMTCT.
Option C: This regimen is inappropriate for this age group. Efavirenz is not recommended for children under 3 years old. Additionally, Tenofovir is used with caution in young children due to concerns about potential bone and renal toxicity.
Option D: This regimen contains Stavudine (d4T) and Didanosine (ddI), which are outdated NRTIs that are no longer recommended for use due to a high risk of severe and irreversible toxicities, including peripheral neuropathy, pancreatitis, and lactic acidosis.

Visual 1: Infographic: Classes of Antiretroviral Drugs (NRTIs, NNRTIs, PIs, INSTIs) with examples and mechanisms of action.
Visual 2: Flowchart: Decision-making algorithm for selecting a first-line ART regimen in pediatric patients, showing different pathways based on age and prior drug exposure.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain First-line antiretroviral therapy (ART) for infants with HIV as background academic context rather than a clinical decision trigger.
Choosing the correct initial ART regimen is critical for long-term viral suppression and preventing immune deterioration in infants with HIV.
Nurses must be vigilant in monitoring for side effects specific to the regimen, such as gastrointestinal intolerance with Lopinavir or bone marrow suppression with Zidovudine.
A key nursing role is educating caregivers on the importance of strict adherence to the medication schedule to prevent drug resistance.

How to Approach the Question

First, identify the specific patient population in the question: 'infants under 3 years old'.
Recall the general structure of a first-line ART regimen: typically two NRTIs plus a third agent from a different class.
Evaluate each option based on the suitability of its components for this specific age group.
Eliminate the option with Efavirenz, as it is not recommended for children under 3 years.
Eliminate the option with Stavudine and Didanosine, as these are known to be toxic and are no longer in use.
Compare the remaining two options. Recognize that a Protease Inhibitor (Lopinavir) is generally preferred over an NNRTI (Nevirapine) as the third agent in this population for better efficacy and a higher resistance barrier.

Concept Tested & Keywords

Qi7Trmxi--K0O49pd9iOLt